Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 zoldonrasib plus chemotherapy versus placebo plus chemotherapy in first-line metastatic KRAS G12D-mutated pancreatic adenocarcinoma
NL-OMON61537Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Zoldonrasib + investigator-choice chemotherapy with Placebo + investigator-choice chemotherapy (2 arms). Primary endpoints: Progression-free survival by investigator and Overall survival. Started Oct 2026; status: recruiting.
02
Drugs
zoldonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON61537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61537.